Lori Friedman

Lori Friedman currently serves as a Board member at NextRNA Therapeutics since September 2023 and has been the Chief Scientific Officer at ORIC Pharmaceuticals since July 2019. Prior to these roles, Lori Friedman held various positions at Genentech from July 2004 to July 2019, including Sr. Director of Translational Oncology and Director of Cancer Signaling and Translational Oncology. Lori Friedman also worked at Exelixis from March 1998 to June 2004, where roles included Director of Signal Transduction Research and Oncology Program Leader. Educational qualifications include a PhD in Molecular and Cell Biology from the University of California, Berkeley, and post-doctoral fellowships in Breast Cancer Genetics at both Cambridge University and the University of Washington, Seattle. Lori Friedman holds a B.S. in Microbiology from the University of Iowa.